Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$2.17 - $3.13 $59,306 - $85,542
27,330 New
27,330 $63.4 Million
Q4 2022

Feb 14, 2023

BUY
$1.99 - $3.52 $54,386 - $96,201
27,330 New
27,330 $64,000
Q3 2022

Nov 14, 2022

SELL
$3.34 - $5.23 $6,145 - $9,623
-1,840 Reduced 6.25%
27,609 $86,000
Q2 2022

Aug 15, 2022

SELL
$2.58 - $4.99 $256,583 - $496,260
-99,451 Reduced 77.15%
29,449 $132,000
Q1 2022

May 11, 2022

BUY
$3.93 - $7.7 $6,476 - $12,689
1,648 Added 1.3%
128,900 $506,000
Q4 2021

Feb 11, 2022

BUY
$7.1 - $12.82 $5,097 - $9,204
718 Added 0.57%
127,252 $904,000
Q3 2021

Nov 12, 2021

BUY
$7.64 - $12.49 $68,706 - $112,322
8,993 Added 7.65%
126,534 $1.39 Million
Q2 2021

Aug 11, 2021

SELL
$8.68 - $27.49 $218,302 - $691,373
-25,150 Reduced 17.63%
117,541 $1.02 Million
Q1 2021

May 13, 2021

SELL
$12.0 - $27.64 $37,896 - $87,287
-3,158 Reduced 2.17%
142,691 $2.17 Million
Q4 2020

Feb 09, 2021

SELL
$11.05 - $16.62 $33,890 - $50,973
-3,067 Reduced 2.06%
145,849 $1.7 Million
Q3 2020

Nov 12, 2020

SELL
$11.69 - $14.54 $40,786 - $50,730
-3,489 Reduced 2.29%
148,916 $1.9 Million
Q2 2020

Aug 12, 2020

BUY
$9.75 - $17.6 $297,960 - $537,856
30,560 Added 25.08%
152,405 $2.27 Million
Q1 2020

May 06, 2020

BUY
$7.54 - $17.05 $187,625 - $424,272
24,884 Added 25.66%
121,845 $1.41 Million
Q4 2019

Feb 14, 2020

BUY
$6.71 - $9.55 $18,902 - $26,902
2,817 Added 2.99%
96,961 $887,000
Q3 2019

Nov 07, 2019

BUY
$6.0 - $9.6 $115,368 - $184,588
19,228 Added 25.67%
94,144 $841,000
Q2 2019

Aug 12, 2019

BUY
$3.77 - $8.67 $147,399 - $338,979
39,098 Added 109.16%
74,916 $628,000
Q1 2019

May 14, 2019

BUY
$2.58 - $3.54 $57,910 - $79,458
22,446 Added 167.86%
35,818 $127,000
Q4 2018

Feb 11, 2019

BUY
$2.65 - $4.26 $35,435 - $56,964
13,372 New
13,372 $38,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $47.3M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.